Progress in Hematology: Non-Malignant, Pre-Malignant, and Malignant Disorders, and Genetically Based Therapies
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".
Deadline for manuscript submissions: closed (25 July 2025) | Viewed by 2257
Special Issue Editor
Interests: hematopathology; molecular genetics; anatomic pathology; clinical pathology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The past two decades have witnessed significant progress in the diagnosis, prognosis, and treatment of many hematologic diseases and in understanding clonal hematopoiesis, including as a potential precursor to hematologic neoplasms. The advances have often been due to an improved understanding of genetics, underlying molecular genetic pathways, and novel genetically or molecularly based therapies. Genetic evaluation, including molecular genetics, cytogenetics, or both, is integral for accurately diagnosing and determining appropriate therapies for many hematologic diseases. Novel genetically based therapies have included curative potential in acquired neoplastic diseases such as chronic myeloid leukemia and inherited non-malignant diseases such as sickle cell anemia. Novel molecular oncologic therapies include genetically targeted therapies in myeloid neoplasms and increasing genetically based applications of measurable residual disease (MRD) detection in hematologic and lymphoid neoplasms. The latter include detecting antigen receptor gene rearrangements following therapy in lymphoid neoplasms such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma, BCR::ABL1 in chronic myeloid leukemia, and MRD evaluation in acute myeloid leukemia.
Hematology includes the study of normal and abnormal hematopoiesis and non-malignant and malignant hematologic disorders, which may be inherited or acquired. Non-malignant hematologic disorders include disorders of (1) iron metabolism, (2) hemoglobin synthesis, including sickle cell anemia and thalassemia, (3) red blood cells, (4) platelets, hemostasis, and thrombosis, and (5) paroxysmal nocturnal hemoglobinuria, aplastic anemia, and (6) inherited bone marrow failure, which may progress to a hematologic neoplasm. Malignant hematologic disorders include myeloid, lymphoid, histiocytic, and dendritic cell neoplasms. These include acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, mastocytosis, adult and pediatric lymphomas, multiple myeloma, other plasma cell neoplasms, plasmacytoid dendritic cell neoplasms, Langerhans cell neoplasms, including Langerhans cell histiocytosis, and histiocytic neoplasms, including anaplastic lymphoma kinase (ALK)+ histiocytosis and Rosai-Dorfman disease. Precursor lesions for myeloid neoplasms, including clonal hematopoiesis and clonal cytopenia of undetermined significance, and tumor-like lymphoid lesions with B-cell or T-cell predominance are also recognized by the 5th edition of the World Health Organization diagnostic classification of tumors of hematolymphoid tissues.
The second edition of our special issue in Genes welcomes research and review articles related to progress in hematology in the spectrum described above.
Dr. Rina Kansal
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematology
- hemoglobinopathies
- erythrocyte disorders
- platelet disorders
- hemophilia
- paroxysmal nocturnal hemoglobinuria
- aplastic anemia
- inherited bone marrow failure
- clonal hematopoiesis
- hematolymphoid tumors
- leukemias
- lymphomas
- multiple myeloma
- clonality
- minimal/measurable residual disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
